Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2017
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2017
SUMMARY
According to the recently published report 'Acyl CoA Desaturase - Pipeline Review, H2 2017'; Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies.
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Stearoyl-CoA desaturase 1 is a protein encoded by the SCD gene. Stearoyl-CoA desaturase-1 plays an important enzyme in fatty acid metabolism. Alteration in SCD1 expression changes the fatty acid profile of these lipids and produces diverse effects on cellular function. High SCD1 expression is correlated with metabolic diseases such as obesity and insulin resistance, whereas low levels are protective against these metabolic disturbances. SCD1 is also involved in the regulation of inflammation and stress in distinct cell types, including ?-cells, adipocytes, macrophages, endothelial cells, and myocytes. Complete loss of SCD1 expression has been implicated in liver dysfunction and several inflammatory diseases such as dermatitis, atherosclerosis, and intestinal colitis.
The report 'Acyl CoA Desaturase - Pipeline Review, H2 2017' outlays comprehensive information on the Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Preclinical, Discovery and Unknown stages are 1, 4, 1 and 1 respectively. Report covers products from therapy areas Gastrointestinal, Metabolic Disorders, Oncology, Dermatology and Infectious Disease which include indications Non-Alcoholic Steatohepatitis (NASH), Acne Vulgaris, Colorectal Cancer, HIV-Associated Lipodystrophy Syndrome, Liver Fibrosis, Metastatic Renal Cell Carcinoma, Non Alcoholic Fatty Liver Disease (NAFLD) and Obesity.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Acyl CoA Desaturase - Pipeline Review, H2 2017'; Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies.
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Stearoyl-CoA desaturase 1 is a protein encoded by the SCD gene. Stearoyl-CoA desaturase-1 plays an important enzyme in fatty acid metabolism. Alteration in SCD1 expression changes the fatty acid profile of these lipids and produces diverse effects on cellular function. High SCD1 expression is correlated with metabolic diseases such as obesity and insulin resistance, whereas low levels are protective against these metabolic disturbances. SCD1 is also involved in the regulation of inflammation and stress in distinct cell types, including ?-cells, adipocytes, macrophages, endothelial cells, and myocytes. Complete loss of SCD1 expression has been implicated in liver dysfunction and several inflammatory diseases such as dermatitis, atherosclerosis, and intestinal colitis.
The report 'Acyl CoA Desaturase - Pipeline Review, H2 2017' outlays comprehensive information on the Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Preclinical, Discovery and Unknown stages are 1, 4, 1 and 1 respectively. Report covers products from therapy areas Gastrointestinal, Metabolic Disorders, Oncology, Dermatology and Infectious Disease which include indications Non-Alcoholic Steatohepatitis (NASH), Acne Vulgaris, Colorectal Cancer, HIV-Associated Lipodystrophy Syndrome, Liver Fibrosis, Metastatic Renal Cell Carcinoma, Non Alcoholic Fatty Liver Disease (NAFLD) and Obesity.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1)
- The report reviews Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Overview
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Companies Involved in Therapeutics Development
Daiichi Sankyo Co Ltd
Galmed Pharmaceuticals Ltd
Johnson & Johnson
Novartis AG
Takeda Pharmaceutical Co Ltd
Thesan Pharmaceuticals Inc
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Drug Profiles
Aramchol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit SCD1 for Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Stearoyl-CoA Desaturase-1 for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit SCD1 for Metastatic Renal Cell Carcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T-3764518 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TSN-2898 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Dormant Products
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Discontinued Products
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Product Development Milestones
Featured News & Press Releases
Nov 07, 2017: Galmed Pharmaceuticals to Provide Corporate Overview at the Stifel 2017 Healthcare Conference
Oct 19, 2017: Galmed Pharmaceuticals to Host Key Opinion Leader Meeting on Non-Alcoholic Steato-Hepatitis (NASH)
Oct 05, 2017: Galmed Pharmaceuticals Announces Publication of Data on Aramchol Mechanism of Action in Hepatology Communications, Data Will Also Be Presented at AASLD
Apr 05, 2017: Galmed Pharmaceuticals to Present at International Liver Congress Data that Shows Aramchol has a Potential Direct Effect on Liver Fibrosis
Jan 09, 2017: Galmed Pharmaceuticals Completes Patient Recruitment for ARREST Phase IIb NASH study
Sep 22, 2016: Galmed Pharmaceuticals and the University of California, San Diego Enter into an Investigator-Initiated Clinical Trial Agreement to Assess Aramchol Effects Juvenile Population
Jun 07, 2016: Galmed Pharmaceuticals Expands its Ongoing Phase IIb ARREST Study to China
Jun 01, 2016: Galmed Pharmaceuticals Randomizes 120th Patient in the ARREST Trial
Mar 30, 2016: Aramchol Demonstrates Significant Anti-Fibrotic Effect in a Pre-clinical Model of Fatty Liver Disease
Mar 01, 2016: Galmed Pharmaceuticals Announces the Enrollment of the First Patient in the ARRIVE Study
Dec 01, 2015: Galmed Pharmaceuticals Announces FDA Clearance of IND of Aramachol for the Treatment of Patients with HIV-Associated Lipodystrophy and Nonalcoholic Fatty Liver Disease
Aug 13, 2015: Galmed Pharmaceuticals Announces the Commencement of Patient Screening in the ARREST Study in the United States and Latin America
Mar 09, 2015: Galmed Pharmaceuticals Announces the Beginning of Enrollment in its Phase IIb ARREST Trial for the Treatment of NASH, as well as the Expansion of the Study to the United States
Jan 28, 2015: Galmed and Perrigo Execute Manufacturing Agreement for Large-Scale Aramchol API Production
Dec 01, 2014: Galmed Pharmaceuticals Completes Analysis of a Pharmacokinetic Study of Aramchol in Healthy Volunteers
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Overview
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Companies Involved in Therapeutics Development
Daiichi Sankyo Co Ltd
Galmed Pharmaceuticals Ltd
Johnson & Johnson
Novartis AG
Takeda Pharmaceutical Co Ltd
Thesan Pharmaceuticals Inc
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Drug Profiles
Aramchol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit SCD1 for Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Stearoyl-CoA Desaturase-1 for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit SCD1 for Metastatic Renal Cell Carcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T-3764518 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TSN-2898 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Dormant Products
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Discontinued Products
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Product Development Milestones
Featured News & Press Releases
Nov 07, 2017: Galmed Pharmaceuticals to Provide Corporate Overview at the Stifel 2017 Healthcare Conference
Oct 19, 2017: Galmed Pharmaceuticals to Host Key Opinion Leader Meeting on Non-Alcoholic Steato-Hepatitis (NASH)
Oct 05, 2017: Galmed Pharmaceuticals Announces Publication of Data on Aramchol Mechanism of Action in Hepatology Communications, Data Will Also Be Presented at AASLD
Apr 05, 2017: Galmed Pharmaceuticals to Present at International Liver Congress Data that Shows Aramchol has a Potential Direct Effect on Liver Fibrosis
Jan 09, 2017: Galmed Pharmaceuticals Completes Patient Recruitment for ARREST Phase IIb NASH study
Sep 22, 2016: Galmed Pharmaceuticals and the University of California, San Diego Enter into an Investigator-Initiated Clinical Trial Agreement to Assess Aramchol Effects Juvenile Population
Jun 07, 2016: Galmed Pharmaceuticals Expands its Ongoing Phase IIb ARREST Study to China
Jun 01, 2016: Galmed Pharmaceuticals Randomizes 120th Patient in the ARREST Trial
Mar 30, 2016: Aramchol Demonstrates Significant Anti-Fibrotic Effect in a Pre-clinical Model of Fatty Liver Disease
Mar 01, 2016: Galmed Pharmaceuticals Announces the Enrollment of the First Patient in the ARRIVE Study
Dec 01, 2015: Galmed Pharmaceuticals Announces FDA Clearance of IND of Aramachol for the Treatment of Patients with HIV-Associated Lipodystrophy and Nonalcoholic Fatty Liver Disease
Aug 13, 2015: Galmed Pharmaceuticals Announces the Commencement of Patient Screening in the ARREST Study in the United States and Latin America
Mar 09, 2015: Galmed Pharmaceuticals Announces the Beginning of Enrollment in its Phase IIb ARREST Trial for the Treatment of NASH, as well as the Expansion of the Study to the United States
Jan 28, 2015: Galmed and Perrigo Execute Manufacturing Agreement for Large-Scale Aramchol API Production
Dec 01, 2014: Galmed Pharmaceuticals Completes Analysis of a Pharmacokinetic Study of Aramchol in Healthy Volunteers
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Daiichi Sankyo Co Ltd, H2 2017
Pipeline by Galmed Pharmaceuticals Ltd, H2 2017
Pipeline by Johnson & Johnson, H2 2017
Pipeline by Novartis AG, H2 2017
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017
Pipeline by Thesan Pharmaceuticals Inc, H2 2017
Dormant Projects, H2 2017
Discontinued Products, H2 2017
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Daiichi Sankyo Co Ltd, H2 2017
Pipeline by Galmed Pharmaceuticals Ltd, H2 2017
Pipeline by Johnson & Johnson, H2 2017
Pipeline by Novartis AG, H2 2017
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017
Pipeline by Thesan Pharmaceuticals Inc, H2 2017
Dormant Projects, H2 2017
Discontinued Products, H2 2017
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
COMPANIES MENTIONED
Daiichi Sankyo Co Ltd
Galmed Pharmaceuticals Ltd
Johnson & Johnson
Novartis AG
Takeda Pharmaceutical Co Ltd
Thesan Pharmaceuticals Inc
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
COMPANIES MENTIONED
Daiichi Sankyo Co Ltd
Galmed Pharmaceuticals Ltd
Johnson & Johnson
Novartis AG
Takeda Pharmaceutical Co Ltd
Thesan Pharmaceuticals Inc
